Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours By Ogkologos - February 17, 2026 255 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DELII study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Precision drug slows progression of advanced breast cancer September 21, 2021 CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated... August 14, 2025 Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 May 20, 2021 Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up August 5, 2025 Load more HOT NEWS Making Transformative Advances against Childhood Cancer: A Conversation with Dr. Doug... Re-Thinking Community 11-Year-Old Cancer Survivor With One Leg Dances With Professional Tapper Lord... Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate...
